Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

NCT07186621 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

286

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Radiotherapy, Adjuvant
Immune Checkpoint Inhibitor
TACE
Narrow Margin

Interventions

DRUG: Sintilimab
RADIATION: radiotherapy
PROCEDURE: TACE

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]